Qitao Yu

机构：Guangxi Medical University

发表论文 6 篇 · 总被引 365 次 · h-index 4

代表论文

• Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309) (2023 · Cancer Cell · 被引 226)
• AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial (2023 · EClinicalMedicine · 被引 105)
• RATIONALE-309: Updated progression-free survival (PFS), PFS after next line of treatment, and overall survival from a phase 3 double-blind trial of tislelizumab versus placebo, plus chemotherapy, as first-line treatment for recurrent/metastatic nasopharyngeal cancer. (2022 · Journal of Clinical Oncology · 被引 27)
• Phase II results of ivonescimab (AK112/ SMT112), a novel PD-1/VEGF bispecific, in combination with chemotherapy for first line treatment of advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGA) in EGFR/ALK. (2023 · Journal of Clinical Oncology · 被引 7)
• Phase 1b/2 study of surufatinib in combination with docetaxel as second-line treatment of advanced driver-gene negative non-squamous non-small cell lung cancer (NSCLC). (2023 · Journal of Clinical Oncology)
• Pd-1/Pd-L1 Inhibitors Plus Anti-Angiogenic Agents with or Without Chemotherapy Versus Pd-1/Pd-L1 Inhibitors Plus Chemotherapy as Second or Later-Line Treatment for Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Retrospective Cohort Study (2022 · SSRN Electronic Journal)